EuroAPI

Historical price data

EuroAPI's mission is to ensure a reliable, high-quality supply of essential active pharmaceutical ingredients (APIs) to secure global healthcare sovereignty. Since its 2022 spin-off and public listing, it has established itself as a critical, independent supplier with a vast portfolio and a resilient European manufacturing footprint. Its strategy is built on four pillars: quality and compliance, customer centricity, operational excellence, and sustainability, positioning it as a key enabler for both established generics and novel drug development.

EuroAPI's platform is a comprehensive, integrated network of chemical and manufacturing expertise spanning complex chemical synthesis, microbial fermentation, and advanced CDMO services for novel modalities like oligonucleotides (Tides) and lipids for lipid nanoparticles (LNPs).

EuroAPI competes with low-cost Asian API manufacturers on value and reliability, differentiates from generalized Western CDMOs through deep expertise in complex chemistry and novel modalities, and leverages its European manufacturing base as a key strategic asset in an era focused on supply chain sovereignty.